CD274 and non-small cell lung carcinoma: In conclusion, for advanced NSCLC patients checkpoint inhibitors showed a more remarkable effect in the PD-L1 ≥ 50% subgroup than in the PD-L1 < 1% or PD-L1 1–49% subgroups.